IDO-1 drugs inhibit tryptophan breakdown and reverses tumor cell suppression of T lymphocytes75; however, because IDO-1 inhibitors do not have a significant role in tumor immunotherapy, IDO-1 inhibitor use alone frequently fails to achieve therapeutic efficacy, similar to the combination with PD-1 checkpoint inhibitors for melanoma76. The gene discussed is IDO1; the disease is neoplasm.